20 research outputs found

    How Ubiquitin Unfolds after Transfer into the Gas Phase

    Get PDF
    The structural evolution of ubiquitin after transfer into the gas phase was studied by electron capture dissociation. Site-specific fragment yields show that ubiquitin’s solution fold is overall unstable in the gas phase, but unfolding caused by loss of solvent is slowest in regions stabilized by salt bridges

    Close-range remote sensing of Saturn's rings during Cassini's ring-grazing orbits and Grand Finale

    Get PDF
    Saturn’s rings are an accessible exemplar of an astrophysical disk, tracing the Saturn system’s dynamical processes and history. We present close-range remote-sensing observations of the main rings from the Cassini spacecraft. We find detailed sculpting of the rings by embedded masses, and banded texture belts throughout the rings. Saturn-orbiting streams of material impact the F ring. There are fine-scaled correlations among optical depth, spectral properties, and temperature in the B ring, but anticorrelations within strong density waves in the A ring. There is no spectral distinction between plateaux and the rest of the C ring, whereas the region outward of the Keeler gap is spectrally distinct from nearby regions. These results likely indicate that radial stratification of particle physical properties, rather than compositional differences, is responsible for producing these ring structures. © 2019 American Association for the Advancement of Science. All rights reserved

    Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

    Get PDF
    We conducted a phase IIa, multi-centre, open label, single arm study (RADICAL; NCT01791985) of AZD4547 (a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2 and 3 receptor tyrosine kinases) administered with anastrozole or letrozole in estrogen receptor positive metastatic breast cancer patients who had become resistant to aromatase inhibitors. After a safety run-in study to assess safety and tolerability, we recruited 52 patients. The primary endpoint was change in tumour size at 12 weeks, and secondary endpoints were to assess response at 6 weeks, 20 weeks and every 8 weeks thereafter and tolerability of the combined treatment. Two partial responses (PR) and 19 stable disease (SD) patients were observed at the 12-week time point. At 28 weeks, according to centrally reviewed Response Evaluation Criteria in Solid Tumours (RECIST) criteria, five PR and 8 SD patients were observed in 50 assessable cases. Overall, objective response rate (5 PR) was of 10%, meeting the pre-specified endpoint. Fourteen patients discontinued due to adverse events. Eleven patients had retinal pigment epithelial detachments which was asymptomatic and reversible in all but one patient. Exploratory ribonucleic acid sequencing (RNA-Seq) analysis was done on patients' samples: 6 differentially-expressed-genes could distinguish those who benefited from the addition of AZD4547
    corecore